Interventional technology firm Medtronic has completed enrollment in an investigational device exemption study of its Endurant abdominal aortic stent graft.
Study data, expected in the second half of 2010, will be used to support a premarket approval application to the U.S. Food and Drug Administration (FDA), according to the Minneapolis-based firm.
Related Reading
Medtronic brings Endeavor stent to Japan, March 30, 2009
Medtronic poses revision for CMS NCD, March 17, 2009
Medtronic completes stent safety study enrollment, February 2, 2009
Boston Scientific, Medtronic bury the hatchet, January 28, 2009
Medtronic installs MRI system in Canada, January 13, 2009
Copyright © 2009 AuntMinnie.com
